Clinical Trials with Melleril (TP21) in the Treatment of Schizophrenia

Abstract

The authors undertook to investigate the effects of two new phenothiazine derivatives on schizophrenic patients. Over a period of two years a series of clinical trials have been carried out on approximately 260 patients, some controlled, some uncontrolled. These drugs, known as Melleril (TP21) and KS75 are chemically related. Although Melleril was ultimately selected as the drug of choice we have, for statistical reasons, included some of the findings with KS75.

A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia

“…Second-generation antipsychotics have not been extensively studied with regard to sexual dysfunction, but they certainly differ from fi rst-generation antipsychotics 56 and also differ from each other. [57][58][59][60][61] Several studies have shown an incidence of sexual dysfunction of 25-60% among patients treated with fi rst-generation antipsychotics 45,62,63 or with risperidone. [57][58][59]64 24% of the patients treated with clozapine and 45% of the patients treated with fi rst-generation antipsychotics present with one or more sexual side effects, including erectile and ejaculatory dysfunction.…”

Accelerated Osteoporosis in Psychiatric Patients: Possible Pathophysiological Processes

“…The decrease in BMD was more marked in males, Reprint requests should be sent to Dr. U. Halbreich, State University of New York at Buffalo, SUNY Clinical Center (BB170), 462 Grider St., Buffalo, NY 14215. eight of whom had lumbar compression fractures (as suggested by dual photon absorptiometry), which had not been previously diagnosed (Halbreich et al 1995). Another group (Schweiger et al 1993) reported decreased BMD in men and women with MDD. Iliac crest bone biopsies performed on chronic psychiatric patients treated with neuroleptic medications (Kutsuma 1993) revealed evidence of altered calcification and histomorphometry.…”

“…Since neuroleptic drugs block central dopaminergic action (Baldessarini 1993) and dopamine is a prolactin-inhibiting factor, the use of neuroleptics frequently results in hyperprolactinemia (Siris et al 1980). The chronic psychotropic-induced hyperprolactinemia may be associated with hypogonadism in both males and females (Levinson and Simpson 1987), which consequently might cause osteoporosis (Klibanski et al 1981;Schlechter et al 1983;Greenspan et al 1986;Ataya et al 1988;Kartaginer et al 1990) (figure 3).…”

“…However, it is unclear whether the observed effects are independent of drug-induced hyperprolactinemia (Laughren et al 1978). In women with schizophrenia, hyperprolactinemia-induced galactorrhea and menstrual irregularities are common (Jensvold et al 1966); with some neurotropics they might occur in up to 50 percent of patients (Sandison et al 1960). Estrogen, or a decrease in its level, might also influence activity of interleukins.…”

The treatment of paraphilias: An historical perspective

“…This follows longstanding evidence for reduction in male libido using almost any psychotropic medication including benperidol (Sterkmans and Geerts, 1966), thioridazine (Sanderson, 1960), fl uphenazine depot (Bartholomew, 1968), clomipramine (Wawrose and Sisto, 1992), lithium (Cesnik and Coleman, 1989) and buspirone (Fedoroff, 1992).…”